Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Epidermal Growth Factor Receptor
73%
Non Small Cell Lung Cancer
56%
Fibroblast Growth Factor 9
32%
Osimertinib
32%
Lung Adenocarcinoma
32%
Neoplasm
26%
Mouse Model
23%
Malignant Neoplasm
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
13%
Lung Tumor
13%
Inflammation
13%
Protein Tyrosine Kinase Inhibitor
13%
Fibroblast Growth Factor 2
12%
Gefitinib
12%
Emphysema
12%
Fibroblast Growth Factor
11%
RNA-Sequencing
10%
Vinorelbine
10%
Nuclease
10%
Afatinib
10%
microRNA 375
10%
Aldehyde Dehydrogenase Isoenzyme 2
10%
Long Term Exposure
10%
CD44v Antigen
10%
Gemcitabine
10%
Combination Therapy
10%
Aptamer
10%
Naquotinib
10%
Nazartinib
10%
Infection
10%
Cetuximab
10%
Alectinib
10%
SARS Coronavirus
10%
Metabotropic Receptor 1
10%
Cyclooxygenase 2
10%
Prostaglandin E2
10%
Celecoxib
10%
Roflumilast
10%
Lung Emphysema
10%
Dinaciclib
10%
Ovary Cancer
10%
Drug Screening
10%
Proteasome Inhibitor
10%
Mouse
9%
Aldehyde Dehydrogenase
8%
Chronic Obstructive Lung Disease
8%
Ceritinib
8%
Biological Marker
7%
Cigarette Smoke
7%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
94%
Cancer Cell
72%
Tyrosine Kinase Inhibitor
33%
Genetics
26%
Allele
25%
FGF9
22%
Exon
21%
Transcription Factors
20%
Aldehyde Dehydrogenase
17%
Gene Expression
16%
Carcinogenesis
14%
Gene Mutation
14%
Wild Type
13%
Downregulation
13%
Basic Fibroblast Growth Factor
12%
Progression Free Survival
12%
Receptor Tyrosine Kinase Inhibitors
11%
Gene Expression Profiling
11%
Methylation
11%
Messenger RNA
11%
DNA Methylation
11%
Drug Sensitivity
11%
Upregulation
10%
Serine Protease
10%
Tissue Factor Pathway Inhibitor
10%
Dynamics
10%
Metabotropic Glutamate Receptor 1
10%
Transdifferentiation
10%
CD44
10%
Transmembrane Domain
10%
Genotyping
10%
MicroRNA
10%
Cetuximab
10%
Microarrays
10%
Aptamer
10%
Fibroblast Growth Factor
10%
KRAS
10%
Factor IX
10%
Cancer Stem Cell
10%
Insulin-Like Growth Factor 1
10%
High Throughput Screening
10%
Proteasome Inhibitor
10%
Fibroblast
10%
Influenza Virus
10%
Reprogramming
10%
Penetrance
10%
Genomics
10%
Germ Cell
10%
Germline
10%
RNA Splicing
10%
Keyphrases
Osimertinib
27%
Non-small Cell Lung Cancer (NSCLC)
20%
EGFR Exon 20 Insertion mutations
15%
Transcription Factor
12%
Organoid Biobank
11%
PTPRH
10%
Synergistic Efficacy
10%
FOXD1
10%
Osimertinib Resistance
10%
Structure-specific
10%
PCR-Invader
10%
FGFR Pathway
10%
Exon 20 mutation
10%
Afatinib
10%
Epidermal Growth Factor Receptor
10%
MiR-375
10%
Lung Organoid
10%
1,2,3-Triazol
10%
N-methyl-3
10%
Autocrine Signaling
10%
Genotype-phenotype Map
10%
In Vitro Modeling
10%
Direct Derivation
10%
Alveolosphere
10%
Combination Therapy
10%
Propagation Potential
10%
FGF9
10%
Activating EGFR mutation
10%
Drug Sensitivity Prediction
10%
Nazartinib
10%
Cetuximab
10%
KRAS G12C mutation
10%
Functional Dissection
10%
Phase II Study
10%
Transmembrane Protease Serine 4
10%
FGFR Alteration
10%
Alectinib
10%
Bypass Signaling
10%
Ceritinib
10%
Methylation Changes
10%
Shift Transformation
10%
EGFR Therapy
10%
Mouse Model
10%
Roflumilast
10%
Lung Adenocarcinoma
10%
Lung Inflammation
10%
Emphysema
10%
Dinaciclib
10%
Anterior Gradient 2
10%
High-throughput Screening
10%
